Inclusion Criteria

- INCLUSION CRITERIA:

Patients must have tumor reactive cells obtained and evaluated while participating in the
Surgery Branch protocol, "Cell Harvest and Preparation for Surgery Branch Adoptive Cell
Therapy Protocols" or on another Institutional Review Board (IRB) approved Surgery Branch
adoptive cell therapy study, i.e. 99-C-0158 or 03-C-0162.

The first ten patients enrolled must have previously received interleukin-2 (IL-2) and
have been either non-responders (progressive disease) or have recurred.

Patients must be greater than or equal to 18 years of age and must have measurable
metastatic melanoma.

Patients of both genders must be willing to practice birth control during treatment and
for four months after receiving the preparative regimen.

Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1.

Absolute neutrophil count greater than 1000/mm^3 without support of filgrastim.

Platelet count greater than 100,000/mm^3.

Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than three
times the upper limit of normal.

Serum creatinine less than or equal to 1.6 mg/dl.

Total bilirubin less than or equal to 2 mg/dl, except in patients with Gilbert's Syndrome
who must have a total bilirubin less than 3 mg/dl.

Must be willing to sign a durable power of attorney.

Patients must be able to understand and sign the Informed Consent document.

Patients with resected or stable brain metastases will be eligible.

Left ventricular ejection fraction (LVEF) greater than or equal to 45%.

Carbon monoxide diffusing capacity (DLCO) greater than or equal to 60% predicted.

CELL INFUSION EXCLUSION CRITERIA:

Less than 30 days has elapsed since any prior systemic therapy at the time the patient
receives the preparative regimen, or less than six weeks since prior nitrosurea therapy.
All patients' toxicities must have recovered to a grade 1 or less or as specified in the
eligibility criteria. Patients may have undergone minor surgical procedures within the
past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified
in the eligibility criteria.

Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

Life expectancy of less than three months.

Systemic steroid therapy required.

Hemoglobin less than 8 g/dl unable to be corrected with transfusion.

Any active systemic infections, coagulation disorders or other active major medical
illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive
stress thallium or comparable test, myocardial infarction, cardiac arrhythmias,
obstructive or restrictive pulmonary disease.

Any form of primary or secondary immunodeficiency. Must have recovered immune competence
after chemotherapy or radiation therapy as evidenced by normal ANC greater than 1000/mm^3
and absence of opportunistic infections. (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible to
its toxicities.)

Seropositive for human immunodeficiency virus (HIV) antibody. (The experimental treatment
being evaluated in this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune competence and thus be less responsive to the
experimental treatment and more susceptible to its toxicities.)

Patients with hepatitis B or hepatitis C will be excluded.

Seronegative for Epstein-Barr virus (EBV).

Patients who are not willing to complete a durable power of attorney (DPA) will be
excluded.

Patients who have received prior preparative regimens with cyclophosphamide and
fludarabine on prior Surgery Branch adoptive cell therapies will be excluded.

The following patients will be excluded because of inability to receive high dose IL-2:

Patients will be excluded if they have a history of electrocardiogram (EKG) abnormalities,
symptoms of cardiac ischemia or arrhythmias and have a LVEF less than 45% on a cardiac
stress test (stress thallium, stress multi-gated acquisition scan (MUGA), dobutamine,
echocardiogram or other stress test).

Similarly, patients who are 50 years old or greater with an LVEF less than 45% will be
excluded.

Patients who have a prolonged history of cigarette smoking or symptoms of respiratory
dysfunction will be excluded if they have an abnormal pulmonary function test as evidenced
by a forced expiratory volume 1 (FEV1) less than 60% predicted.